Weight loss drugs like GLP-1s and tirzepatide reduce appetite and silence persistent thoughts about food, which is translating to concerns about food sales—and some swift pivots in the food industry. (WSJ’s covered this here, here, and here, if you’ve got a subscription.)
Some also wonder how these drugs will impact the culture around food—specifically, the way we celebrate life’s occasions with feasts or enjoy the company of friends around drinks and noshes.
While big food companies have the intel and budget to jump in—Nestlé’s already announced a line of portion-controlled frozen meals called Vital Pursuit—chefs, small businesses, and restaurants are looking for more info to help them meet what will definitely be growing demand.
San Francisco’s chapter of Les Dames D’Escoffier International, an organization for women in food, beverage and hospitality, is helping culinary pros start thinking about how to change menus, products, and meals.
In March I was a panelist on a virtual panel discussion, “The Weight of Ozempic®: What happens when we no longer care about food?” inspired by a Washington Post article, “Food is one of life’s great pleasures. Will weight-loss drugs end that?” (paywall) by former WashPo business of food reporter Laura Reiley. She was one of panelists for LDEI’s convo, as was food trendologist Kara Nielsen and Marion Nestle, PhD, author of Food Politics and the Paulette Goddard Professor of Nutrition, Food Studies and Public Health, Emerita, at New York University. As a panelist, I shared my thoughts as both a culinary pro and as someone who’s taken Ozempic and Mounjaro.
My quick takes on how things might change:
Watch “The Weight of Ozempic” panel discussion – it’s about 90 minutes.
Comments will load here
Be the first to comment